沉默毒性:一种罕见的5 - 甲诱导的高氨基血性脑病变
Areti Kalfoutzou1, Cleopatra Rapti2, Eleftheria Bagiokou3
1Second Propaedeutic Department of Internal Medicine, Attikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Oncoscience
|December 25, 2025
概括
超氨性脑病变 (HE) 是一种严重的神经疾病,由高氨水平引起. 化疗药物5-fluorouracil (5-FU) 可以诱导HE,需要在患有神经症状的患者中监测氨.
科学领域:
- 神经学 神经学
- 在瘤学瘤学.
- 毒理学 毒理学 毒理学
背景情况:
- 超氨性脑病变 (HE) 是一种神经疾病,其特征是由于血清氨量升高而改变精神状态.
- 氨是一种蛋白质代谢的副产品,它穿过血脑屏障,起到神经毒素的作用,导致可逆性脑损伤.
- 药物诱导的HE是某些化疗剂的已知并发症,包括5-甲 (5-FU).
研究的目的:
- 报告药物诱导的高血性脑病变病例后的5-甲 (5-FU) 管理.
- 要强调监测血清氨水平在接受5-FU并表现出神经症状的患者中的重要性.
- 强调在考虑在这些患者中重新进行5FU时需要专家咨询的必要性.
主要方法:
- 一个63岁的女性患者的病例报告.
- 在5-FU化疗后的临床表现.
- 血清氨水平和神经状态的监测.
主要成果:
- 患者经历了5 - FU管理后意识减弱的反复发作.
- 血清氨水平升高与神经系统恶化相关.
- 及时识别和管理导致可逆的神经缺陷.
结论:
- 5-甲 (5-FU) 可以诱导高血性脑病变 (HE).
- 血清氨监测对于在5-FU治疗中出现神经症状的患者至关重要.
- 需要仔细考虑和专家咨询,在HE之后重新挑战5-FU.
相关概念视频
Anticholinesterase Agents: Poisoning and Treatment
1.5K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.5K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
564
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
564
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
165
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
165
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
234
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
234
Urea Cycle
49.5K
The urea cycle describes how liver cells convert ammonia to urea. Ammonia is a toxic waste product of protein catabolism. Land animals must convert ammonia into the less toxic urea which can be safely eliminated by the kidneys through urine. Marine animals excrete ammonia directly, and the surrounding water dilutes the ammonia to safe levels.
49.5K
Renal Failure: Dose Adjustments
401
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
401


